Key facts
as of Sep 2026- It has raised $41.8M; the latest was Seed Round ($41.8M) in Dec 2025.
- Notable investors include Sofinnova Partners, M Ventures, NRW BANK, Panakes Partners, AbbVie Ventures — 7 tracked in total.
- 3 institutional filers report fund marks on DISCO Pharmaceuticals across 22 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for DISCO Pharmaceuticals
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in DISCO Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
3 filers · latest Apr 20263 SEC-registered funds reported 22 fair-value marks on DISCO Pharmaceuticals between Apr 2025 and Apr 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for DISCO Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DISCO Pharmaceuticals
Operator of a surfaceome mapping platform intended to improve patient care using transformative cell discovery technology. The company's technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner and permits unraveling comprehensive target information that neither standard proteomics nor genome or transcriptome sequencing can provide, enabling companies with cancer-selective therapies, with the potential to boost efficacy and reduce side effects for patients.
- Sector
- Healthcare
- HQ
- Cologne, Germany
- Founded
- 2022
- Employees
- 37
- Website
- discopharma.de/
- Ownership
- Privately Held (backing)